Search results
Results from the WOW.Com Content Network
Litifilimab is an investigational drug being evaluated for the treatment of cutaneous lupus erythematosus and systemic lupus erythematosus. It is an anti- BDCA2 monocolonal antibody. [ 1 ] [ 2 ] [ 3 ]
The oral drug, brepocitinib, did not meet the primary study goal of reduction in disease activity at week 52 in patients of SLE, in which the immune system that normally helps protect the body ...
The Lupus Research Alliance has given more money to lupus research than any non-governmental agency in the world. [4] As of 2015 the LRA's cumulative research commitment was over $100,000,000, [ 1 ] making it the largest lupus research organization and the only organization the funds lupus biomedical research internationally.
On 13 February 2007, HGS and GSK announced the initiation of the first of two Phase III clinical trials of belimumab in patients with active lupus erythematosus. [21] Two Phase III clinical studies were conducted, involving a total of 1,684 patients with scores of ≥6 on the SELENA-SLEDAI assessment of lupus activity.
Ianalumab (INN; [1] development code VAY736) is a monoclonal antibody that is being investigated for autoimmune hepatitis, multiple sclerosis, pemphigus vulgaris, rheumatoid arthritis, Sjogren's disease, and systemic lupus erythematosus. [2] [3] [4] This drug is being developed by Novartis. In 2021 ianalumab was undergoing Phase II/III trials.
The Centers for Disease Control and Prevention estimates that more than 200,000 people in the U.S. have lupus, though the Lupus Foundation of America puts the total much higher: roughly 1.5 ...
Dapirolizumab pegol is "a polyethylene glycol conjugated anti-CD40L Fab fragment" developed by Biogen for systemic lupus erythematosus. [ 1 ] [ 2 ] [ 3 ] References
A new treatment is being trialled for the autoimmune condition